The Latest Cardiac and Vascular News
The permanent heart implant is the only FDA-approved device for the reduction of stroke risk in patients with non-valvular atrial fibrillation LAGUNA HILLS, CA – Oct. 28, 2021 — The MemorialCare Heart & Vascular Institute at Saddleback Medical Center recently performed its 100th WATCHMAN™ Left Atrial Appendage Closure Device procedure, […]
TIANJIN, China, Oct. 27, 2021 /PRNewswire/ — SINOMED, a leading international medical device company, announced that the clinical trial results for its HT Supreme® Drug-Eluting Stent (DES) System has been published in Circulation. The article described results from the PIONEER III trial where investigators demonstrated equivalence in safety and effectiveness between the […]
TAMPA, Fla., Oct. 27, 2021 /PRNewswire/ — Keystone Heart Ltd., a Venus Medtech Company, today announced a key milestone in Europe with the TriGUARD 3 Cerebral Embolic Protection (CEP) Device. The device was granted CE mark in March of 2020 and, since launch, utilized in fourteen countries with zero physician-reported strokes. The TriGUARD 3 CEP device is the only […]
Market availability of the cardiovascular disease prevention module co-developed with Bayer demonstrates One Drop’s continued expansion into new therapeutic areas NEW YORK, Oct. 27, 2021 /PRNewswire/ — One Drop, a leader in precision health solutions for people living with chronic conditions worldwide, today announced the release of a digital, AI-enabled cardiovascular disease […]
Study Evaluates Effectiveness of QuikClot Control+® Hemostatic Device in Patients Undergoing Cardiac Surgery WAYNE, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in a clinical study evaluating the performance of the QuikClot Control+® Hemostatic Device […]
Malmö, Sweden, October 27, 2021 Acarix granted US CPT reimbursement code for CADScor System The editorial panel of the American Medical Association (AMA) today approved the Category III CPT® (CPT III) code application for the Acarix CADScor System®. The application was actively endorsed by the American College of Cardiology (ACC) […]
New Case Report Reveals Opportunity to Become First-Line Therapy for Patients SUNNYVALE, Calif.–(BUSINESS WIRE)–EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced the publication of a case report demonstrating the WiSE™ CRT System’s ability to successfully deliver leadless Left Bundle Branch Area Pacing […]
Investment to support Cardurion’s further evolution into a cardiovascular leader BOSTON–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment […]
Reports Third Quarter Revenues of $11.6 Billion, an Increase of 10% YoY Posts Third Quarter Earnings Per Share of $0.69 and Non-GAAP EPS of $2.00 Advances Product Pipeline with Significant Regulatory and Clinical Milestones Achieves FDA Priority Review for Third Distinct Checkpoint Inhibitor, Relatlimab and Nivolumab Fixed-Dose Combination, as Treatment for […]
– Acceleron expects to report approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics […]
